ABSTRACT

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by multiple pathologies in which sustained inflammatory activity leads to progressive tissue destruction and organ damage. One of the main proinflammatory cytokines playing a key role in autoimmune diseases such as rheumatoid arthritis (RA) or SLE, is tumor necrosis factor (TNF) alpha.

Areas covered

The introduction of TNF-alpha inhibitors revolutionized the treatment of RA and other conditions including psoriatic arthritis and ankylosing spodylitis. We review here the efficacy and safety of TNF-alpha blockers in SLE focussing on why it has not been more widely used since TNF-alpha was reported to be increased in SLE patients and to correlate with disease activity.

Expert opinion

We summarize the reported SLE cases that have received TNF-alpha blockers and the main results to date. We reflect on whether there is a case to reconsider the use of TNF-alpha blockade in SLE.

中文翻译：

---

系统性红斑狼疮患者使用抗 TNF-α 疗法。我们现在在哪？

摘要

介绍

系统性红斑狼疮 (SLE) 是一种自身免疫性风湿性疾病，其特征在于多种病理，其中持续的炎症活动导致进行性组织破坏和器官损伤。在类风湿性关节炎 (RA) 或 SLE 等自身免疫性疾病中起关键作用的主要促炎细胞因子之一是肿瘤坏死因子 (TNF) α。

涵盖的领域

TNF-α 抑制剂的引入彻底改变了 RA 和其他疾病的治疗，包括银屑病关节炎和强直性脊柱炎。我们在此回顾了 TNF-α 阻滞剂在 SLE 中的疗效和安全性，重点是为什么它没有被更广泛地使用，因为据报道 TNF-α 在 SLE 患者中增加并与疾病活动相关。

专家意见

我们总结了已报告的接受 TNF-α 阻滞剂的 SLE 病例以及迄今为止的主要结果。我们反思是否存在重新考虑在 SLE 中使用 TNF-α 阻断剂的案例。